Showing results (1771-1780 of 31,365) with videos related to
Sort By:
Pageof 3,137
Journal of Medicinal Chemistry|April 1, 1987
S-[(N,N'-diarylamidino)methyl] diethyldithiocarbamates and related amides as potential radioprotectantsT P PantevJournal of Medicinal Chemistry|April 1, 1987
Synthesis and pharmacological evaluation of gamma-aminobutyric acid analogues. New ligand for GABAB sitesP Berthelot, C Vaccher, A Musadad, et al.Journal of Medicinal Chemistry|April 1, 1987
Resolution of racemic carbocyclic analogues of purine nucleosides through the action of adenosine deaminase. Antiviral activity of the carbocyclic 2'-deoxyguanosine enantiomersJ A Secrist, J A Montgomery, Y F Shealy, et al.Journal of Medicinal Chemistry|October 1, 1986
Design and synthesis of potent and specific renin inhibitors containing difluorostatine, difluorostatone, and related analoguesS Thaisrivongs, D T Pals, W M Kati, et al.Journal of Medicinal Chemistry|July 1, 1978
A new class of antimalarial drugs: derivatives of benzothiopyransR K Razdan, R J Bruni, A C Mehta, et al.Journal of Medicinal Chemistry|March 24, 2022
Synthesis and Characterization of Transition-State Analogue Inhibitors against Human DNA Methyltransferase 1Farah Lamiable-Oulaidi, Rajesh K Harijan, Karl J Shaffer, et al.Journal of Medicinal Chemistry|March 2, 2022
Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery EffortsZhouling Xie, Shuzeng Hou, Xiaoxiao Yang, et al.Journal of Medicinal Chemistry|March 9, 2022
Discovery and Optimization of Biaryl Alkyl Ethers as a Novel Class of Highly Selective, CNS-Penetrable, and Orally Active Adaptor Protein-2-Associated Kinase 1 (AAK1) Inhibitors for the Potential Treatment of Neuropathic PainGuanglin Luo, Ling Chen, Walter A Kostich, et al.Journal of Medicinal Chemistry|March 16, 2022
Leveraging Structure-Based Drug Design to Identify Next-Generation MAT2A Inhibitors, Including Brain-Penetrant and Peripherally Efficacious LeadsMingzong Li, Zenon Konteatis, Nelamangala Nagaraja, et al.Journal of Medicinal Chemistry|March 18, 2022
Discovery of Reversible Covalent Bruton's Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib)Timothy D Owens, Ken A Brameld, Erik J Verner, et al.Pageof 3,137